MRK Merck & Co., Inc.

Range, yield & payout streak

Based on Yahoo annual dividend totals through 2025 (excludes incomplete 2026).

BDC / cash pass-through vs ordinary dividend

Ordinary corporate dividend — paid from corporate earnings/cash at the board’s discretion. Unlike BDCs/REITs, there is usually no pass-through distribution mandate. Coverage (earnings/FCF vs dividend), balance sheet, and streak matter more than yield height.

Remember: high yield ≠ safer. Pass-through vehicles (BDC / REIT) can show high distributions by design while carrying credit, rate, or occupancy risk.

Dividend safety rating

High yield ≠ safer — elevated yield often prices higher risk or return-of-capital. Payout streak (non-decreasing annual totals): ~22 years. Yahoo payoutRatio raw=2.688 (interpret cautiously).

Dividend history trend (recent payments)

Sourced from Yahoo via yfinance. Gaps or missing rows = data unavailable, not zeroes we invented.

Pass-through / BDC mechanics (deeper)

Ordinary corporate dividend — paid from corporate earnings/cash at the board’s discretion. Unlike BDCs/REITs, there is usually no pass-through distribution mandate. Coverage (earnings/FCF vs dividend), balance sheet, and streak matter more than yield height.

Advanced frame: for ordinary payers, focus on earnings/FCF coverage and balance-sheet flexibility. For REITs, focus on AFFO/FFO trends, occupancy, and debt ladders. For BDCs, focus on NII vs distribution, non-accruals, leverage vs statutory limits, and NAV drift. This page still is not a Crystal Signals entry card — no Counsel fire / manage stamp here.

Full company blurb

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.